261 related articles for article (PubMed ID: 30706395)
61. Interaction of adenovirus with antibodies, complement, and coagulation factors.
Allen RJ; Byrnes AP
FEBS Lett; 2019 Dec; 593(24):3449-3460. PubMed ID: 31660588
[TBL] [Abstract][Full Text] [Related]
62. Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs.
Heiniö C; Sorsa S; Siurala M; Grönberg-Vähä-Koskela S; Havunen R; Haavisto E; Koski A; Hemminki O; Zafar S; Cervera-Carrascon V; Munaro E; Kanerva A; Hemminki A
Hum Gene Ther; 2019 Jun; 30(6):740-752. PubMed ID: 30672366
[TBL] [Abstract][Full Text] [Related]
63. Adenovirus and adeno-associated virus vectors.
Lai CM; Lai YK; Rakoczy PE
DNA Cell Biol; 2002 Dec; 21(12):895-913. PubMed ID: 12573049
[TBL] [Abstract][Full Text] [Related]
64. The improvement of adenovirus vector production by increased expression of coxsackie adenovirus receptor.
Liu X; Wang Y; Niu H; Zhang X; Tan WS
Biotechnol Lett; 2009 Jul; 31(7):939-44. PubMed ID: 19330491
[TBL] [Abstract][Full Text] [Related]
65. Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review).
Athanasopoulos T; Fabb S; Dickson G
Int J Mol Med; 2000 Oct; 6(4):363-75. PubMed ID: 10998427
[TBL] [Abstract][Full Text] [Related]
66. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.
Yao X; Yoshioka Y; Morishige T; Eto Y; Narimatsu S; Kawai Y; Mizuguchi H; Gao JQ; Mukai Y; Okada N; Nakagawa S
Mol Ther; 2011 Sep; 19(9):1619-25. PubMed ID: 21673661
[TBL] [Abstract][Full Text] [Related]
67. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
68. Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.
Jönsson F; Kreppel F
Virus Genes; 2017 Oct; 53(5):692-699. PubMed ID: 28755290
[TBL] [Abstract][Full Text] [Related]
69. Adenovirus vector production and purification.
Silva AC; Peixoto C; Lucas T; Küppers C; Cruz PE; Alves PM; Kochanek S
Curr Gene Ther; 2010 Dec; 10(6):437-55. PubMed ID: 21054247
[TBL] [Abstract][Full Text] [Related]
70. The induction of inflammation by adenovirus vectors used for gene therapy.
Cotter MJ; Muruve DA
Front Biosci; 2005 May; 10():1098-105. PubMed ID: 15769609
[TBL] [Abstract][Full Text] [Related]
71. Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy.
Amalfitano A; Parks RJ
Curr Gene Ther; 2002 May; 2(2):111-33. PubMed ID: 12109210
[TBL] [Abstract][Full Text] [Related]
72. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.
Joseph PM; O'Sullivan BP; Lapey A; Dorkin H; Oren J; Balfour R; Perricone MA; Rosenberg M; Wadsworth SC; Smith AE; St George JA; Meeker DP
Hum Gene Ther; 2001 Jul; 12(11):1369-82. PubMed ID: 11485629
[TBL] [Abstract][Full Text] [Related]
73. Adenovirus: the first effective in vivo gene delivery vector.
Crystal RG
Hum Gene Ther; 2014 Jan; 25(1):3-11. PubMed ID: 24444179
[No Abstract] [Full Text] [Related]
74. [Construction of a recombinant adenovirus vector for interferon-gamma-inducible protein 10 and the adenovirus preparation].
Shao ZY; Liu ZF; Peng Y; Xu J; Deng P; Jiang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1552-5. PubMed ID: 17121697
[TBL] [Abstract][Full Text] [Related]
75. Gene transfer into rat brain using adenoviral vectors.
Thomas CE; Abordo-Adesida E; Maleniak TC; Stone D; Gerdes CA; Lowenstein PR
Curr Protoc Neurosci; 2001 May; Chapter 4():Unit 4.24. PubMed ID: 18428484
[TBL] [Abstract][Full Text] [Related]
76. Ex vivo transfer of the Hoxc-8-interacting domain of Smad1 by a tropism-modified adenoviral vector results in efficient bone formation in a rabbit model of spinal fusion.
Douglas JT; Rivera AA; Lyons GR; Lott PF; Wang D; Zayzafoon M; Siegal GP; Cao X; Theiss SM
J Spinal Disord Tech; 2010 Feb; 23(1):63-73. PubMed ID: 20084034
[TBL] [Abstract][Full Text] [Related]
77. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector.
Toloza EM; Hunt K; Swisher S; McBride W; Lau R; Pang S; Rhoades K; Drake T; Belldegrun A; Glaspy J; Economou JS
Cancer Gene Ther; 1996; 3(1):11-7. PubMed ID: 8785705
[TBL] [Abstract][Full Text] [Related]
78. GMP-Compliant Adenoviral Vectors for Gene Therapy.
Arjmand B; Alavi-Moghadam S; Payab M; Goodarzi P; Sheikh Hosseini M; Tayanloo-Beik A; Rezaei-Tavirani M; Larijani B
Methods Mol Biol; 2021; 2286():237-250. PubMed ID: 32504293
[TBL] [Abstract][Full Text] [Related]
79. Use of adenoviral vectors as veterinary vaccines.
Ferreira TB; Alves PM; Aunins JG; Carrondo MJ
Gene Ther; 2005 Oct; 12 Suppl 1(Suppl 1):S73-83. PubMed ID: 16231058
[TBL] [Abstract][Full Text] [Related]
80. Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors.
Vassalli G; Büeler H; Dudler J; von Segesser LK; Kappenberger L
Int J Cardiol; 2003 Aug; 90(2-3):229-38. PubMed ID: 12957756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
